BLUENEUTRAL

Revenue Growth (YoY)

108.4%

Higher than 100% of Healthcare sector peers

Updated 1078h ago

Sector Performance

100th percentile

BLUE

108.4%

Sector Median

6.2%

Sector Avg

3.8%

📊

Deep Analysis

Revenue Growth (Year-over-Year) measures how much a company's sales increased compared to the same period one year earlier; bluebird bio's 108.4% means its revenue more than doubled from the prior year.

This far exceeds the Healthcare sector median of 6.2%, placing the company in the 100th percentile among sector peers — the highest growth rate of the group. Trend data for this metric is not available: the year-over-year change is listed as N/A, the quarter-over-quarter change is N/A, and there is only a single reported historical value covering the last eight quarters. With an extremely high current level but no trend history to show consistency or acceleration, the combination suggests an isolated spike that could be due to a one-time event, raising uncertainty about future growth. This high but unverified revenue growth supports the overall NEUTRAL verdict because the lack of trend data prevents a clear bullish or bearish conclusion — the strong level alone does not confirm a durable improvement.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about BLUE?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does BLUE's Revenue Growth (YoY) compare to its sector?

BLUE's Revenue Growth (YoY) of 108.4% compares to a Healthcare sector median of 6.2%, placing it in the 100th percentile.

Who are BLUE's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: AMGN (5.8%), CPRX (5.6%), HIMS (3.8%), BAX (2.9%), BMY (2.6%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.